Pharmacological mechanisms of puerarin in the treatment of Parkinson's disease: An overview

被引:2
|
作者
Zhang, Nianping [1 ,2 ]
Guo, Peng [3 ]
Zhao, Yan [4 ]
Qiu, Xiao [2 ]
Shao, Shuai [5 ]
Liu, Zhenzhong [6 ]
Gao, Zong [7 ]
机构
[1] Shandong Univ Tradit Chinese Med, Postdoctoral Mobile Stn, Jinan 250355, Shandong, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan 250355, Shandong, Peoples R China
[3] Jinan Third Peoples Hosp, Dept Neurol, Jinan 250132, Shandong, Peoples R China
[4] Jinan Third Peoples Hosp, Dept Hand & Upper Limb Surg, Jinan 250132, Shandong, Peoples R China
[5] Jingmen Peoples Hosp, Dept Reprod Med, Jingmen 448000, Hubei, Peoples R China
[6] North Sichuan Med Coll, Sch Publ Hlth, Nanchong 637100, Peoples R China
[7] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Neurosurg, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China
关键词
Parkinson 's disease; Puerarin; Pharmacological mechanism; Dopaminergic neurons; Traditional Chinese medicine monomer; PROTECTS DOPAMINERGIC-NEURONS; UBIQUITIN-PROTEASOME SYSTEM; IN-VITRO; ISOFLAVONE PUERARIN; COUPLED RECEPTOR; OXIDATIVE STRESS; PI3K/AKT PATHWAY; O-GLCNACYLATION; MOUSE MODELS; PC12; CELLS;
D O I
10.1016/j.biopha.2024.117101
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Puerarin, a monomer of traditional Chinese medicine, is a key component of Pueraria radix . Both clinical and experimental researches demonstrated that puerarin has therapeutic effects on Parkinson 's disease (PD). Puerarin 's pharmacological mechanisms include: 1) Anti-apoptosis. Puerarin inhibits cell apoptosis through the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) and c-Jun N-terminal kinase (JNK) signaling pathways. Puerarin also exerts a hormone-like effect against cell apoptosis; 2) Anti-oxidative stress injury. Puerarin inhibits the Nrf2 nuclear exclusion through the GSK-3 beta/Fyn pathway to promote the Nrf2 accumulation in the nucleus, and then promotes the antioxidant synthesis through the Nrf2/ARE signaling pathway to protect against oxidative stress; 3) Neuroprotective effects by intervening in the ubiquitinproteasome system (UPS) and autophagy-lysosomal pathway (ALP). Puerarin significantly enhances the activity of chaperone-mediated autophagy (CMA), which downregulates the expression of alpha-synuclein, reduces its accumulation, and thus improves the function of damaged neurons. Additionally, puerarin increases proteasome activity and decreases ubiquitin-binding proteins, thereby preventing toxic accumulation of intracellular proteins; 4) Alleviating inflammatory response. Puerarin inhibits the conversion of microglia to the M1 phenotype while inducing the transition of microglia to the M2 phenotype. Furthermore, puerarin promotes the secretion of anti-inflammatory factor and inhibits the expression of pro-inflammatory factors; 5) Increasing the levels of dopamine and its metabolites. Puerarin could increase the levels of dopamine, homovanillic acid (HVA) and 3,4dihydroxyphenylacetic acid (DOPAC) in the striatum; 6) Promoting neurotrophic factor expression and neuronal repair. Puerarin increases the expression of glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), thereby exerting a neuroprotective effect. Moreover, the regulation of the gut microbiota by puerarin may be a potential mechanism for the treatment of PD. The current review discusses the molecular mechanisms of puerarin, which may provide insight into the active components of traditional Chinese medicine in the treatment of PD.
引用
收藏
页数:22
相关论文
共 50 条
  • [41] Effectiveness of Acupuncture in the Treatment of Parkinson's Disease: An Overview of Systematic Reviews
    Huang, Jinke
    Qin, Xiaohui
    Cai, Xiaowen
    Huang, Yong
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [42] Anhedonia in Parkinson's Disease: An Overview
    Loas, Gwenole
    Krystkowiak, Pierre
    Godefroy, Olivier
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2012, 24 (04) : 444 - 451
  • [43] An overview of pain in Parkinson's disease
    Tai, Yi-Cheng
    Lin, Chin-Hsien
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2020, 2 : 1 - 8
  • [44] Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management
    Carbone, Federico
    Djamshidian, Atbin
    CNS DRUGS, 2024, 38 (06) : 443 - 457
  • [45] Pharmacological Progresses of Puerarin in the Prevention and Treatment of Atherosclerosis
    Jia, Liyi
    Xing, Lu.
    Li, Pengquan
    Chu, Haiqing
    Zhou, Xin
    Qin, Wei
    He, Chunxia
    Li, Huijin
    Zhao, Dong
    Zhang, Juan
    Cao, Huiling
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 (04) : 884 - 894
  • [46] Metabotropic glutamate receptors : Potential pharmacological targets in Parkinson's disease treatment
    Amalric, M
    Turle-Lorenzo, N
    Lopez, S
    NEUROPHARMACOLOGY, 2005, 49 : 231 - 231
  • [47] Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future
    Peter Jenner
    Translational Neurodegeneration, 4
  • [48] Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future
    Jenner, Peter
    TRANSLATIONAL NEURODEGENERATION, 2015, 4
  • [49] Kinesitherapy is a basic element of non-pharmacological treatment of Parkinson's disease
    Kamakinova, A. B.
    Golubev, V. L.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (10) : 69 - 73
  • [50] Progress of Pharmacological Approaches in Parkinson's Disease
    Zeuner, Kirsten L.
    Schaeffer, Eva
    Hopfner, Franziska
    Brueggemann, Norbert
    Berg, Daniela
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (05) : 1106 - 1120